{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:31Z","timestamp":1793291611941,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Prostate Cancer Foundation and Movember","id":[{"id":"https:\/\/ror.org\/01npwtv09","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01113-8","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:24:19Z","timestamp":1775096659000},"page":"990-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-8245","authenticated-orcid":false,"given":"Santosh","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":false,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-9095","authenticated-orcid":false,"given":"Chenxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyotae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-2838","authenticated-orcid":false,"given":"Jane","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-8542","authenticated-orcid":false,"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-3617","authenticated-orcid":false,"given":"Russell Z.","family":"Szmulewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-0741","authenticated-orcid":false,"given":"Daniel C.","family":"Danila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-473X","authenticated-orcid":false,"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"1113_CR1","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"1113_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2021.02.042","volume":"150","author":"H Scher","year":"2021","unstructured":"Scher H, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. Eur J Cancer. 2021;150:83\u201394.","journal-title":"Eur J Cancer"},{"key":"1113_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J Clin Oncol. 2019;37:1120\u20139.","journal-title":"J Clin Oncol"},{"key":"1113_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/jcb.2020.2163","volume":"9","author":"D Lu","year":"2020","unstructured":"Lu D, Master SR, Duvvuri A, Westra WH, Boral D, Low PS, et al. Detection and characterization of circulating tumor cells in non-metastatic prostate cancer patients. J Circ Biomark. 2020;9:13\u201319.","journal-title":"J Circ Biomark"},{"key":"1113_CR5","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, et al. Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020;4:PO.20.00200.","DOI":"10.1200\/PO.20.00200"},{"key":"1113_CR6","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-20-3471","volume":"27","author":"LC Brown","year":"2021","unstructured":"Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, et al. Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide. Clin Cancer Res. 2021;27:4077\u201388.","journal-title":"Clin Cancer Res"},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.3390\/cancers12092639","volume":"12","author":"P K\u00f6nig","year":"2020","unstructured":"K\u00f6nig P, Krahn T, G\u00fcnther M, Schmid KW, Schultze-Seemann W, Jakse G, et al. Detection of circulating tumor cells using a novel separation method: clinical implications in prostate cancer patients. Cancers. 2020;12:2639.","journal-title":"Cancers"},{"key":"1113_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/gcc.22824","volume":"59","author":"S Gupta","year":"2020","unstructured":"Gupta S, Hovelson DH, Kemeny G, Halabi S, Foo W-C, Anand M, et al. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration-resistant prostate cancer. Genes Chromosomes Cancer. 2020;59:225\u201339.","journal-title":"Genes Chromosomes Cancer"},{"key":"1113_CR9","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/1541-7786.MCR-20-0975","volume":"19","author":"S Gupta","year":"2021","unstructured":"Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, et al. Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer. Mol Cancer Res. 2021;19:1040\u201350.","journal-title":"Mol Cancer Res"},{"key":"1113_CR10","doi-asserted-by":"crossref","unstructured":"Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol. 2018;4:1179\u201386.","DOI":"10.1001\/jamaoncol.2018.1621"},{"key":"1113_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5772\/60725","volume":"4","author":"SL Werner","year":"2015","unstructured":"Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene SB, et al. Analytical validation and capabilities of the Epic CTC Platform: enrichment-free circulating tumour cell detection and characterization. J Circ Biomark. 2015;4:3.","journal-title":"J Circ Biomark"},{"key":"1113_CR12","first-page":"e22034","volume":"33","author":"S Jia","year":"2015","unstructured":"Jia S, Baird S, Anderson A, Werner S, Petersen J, Huw L, et al. Circulating tumor cell (CTC) detection, N-terminal androgen receptor (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC). 2015 ASCO annual meeting abstracts. Tumor Biol. 2015;33:e22034.","journal-title":"Tumor Biol"},{"key":"1113_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e17021","volume":"41","author":"E Barnett","year":"2023","unstructured":"Barnett E, Gupta S, Erazo T, Lam E, Carbone E, Zanone M, et al. Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer. J Clin Oncol. 2023;41:e17021.","journal-title":"J Clin Oncol"},{"key":"1113_CR14","doi-asserted-by":"crossref","unstructured":"Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES. Clinical utility of CLIA-grade AR-V7 testing in patients with metastatic castration-resistant prostate cancer.JCO Precis Oncol. 2017;2017:PO.17.00127.","DOI":"10.1200\/PO.17.00127"},{"key":"1113_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","volume":"32","author":"S Halabi","year":"2014","unstructured":"Halabi S, Lin CY, Kelly WK, Fizazi K, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671\u20137.","journal-title":"J Clin Oncol"},{"key":"1113_CR16","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Clin Cancer Res. 2008;14:6302\u20139.","journal-title":"Clin Cancer Res"},{"key":"1113_CR17","doi-asserted-by":"publisher","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E H\u00f6rnberg","year":"2011","unstructured":"H\u00f6rnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration resistance and short survival. PLoS ONE. 2011;6:e19059.","journal-title":"PLoS ONE"},{"key":"1113_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868031","volume":"12","author":"T Khan","year":"2022","unstructured":"Khan T, Becker TM, Scott KF, Descallar J, de Souza P, Chua W, et al. Prognostic and predictive value of liquid biopsy-derived androgen receptor variant 7 (AR-V7) in prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:868031.\u00a0","journal-title":"Front Oncol"},{"key":"1113_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441\u20139.","journal-title":"JAMA Oncol"},{"key":"1113_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","volume":"70","author":"J Welti","year":"2016","unstructured":"Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, et al. 2020 analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:599\u2013608.","journal-title":"Eur Urol"},{"key":"1113_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36:76\u201388.","journal-title":"Ann Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01113-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:23Z","timestamp":1793289743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01113-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SG, CY, SG, and JM have none. SH served as a member of the Data Safety Monitoring for BMS, Beigene, CG Oncology, Janessen, and Sanofi. She received research funding (institution) from the American Society of Clinical Oncology, Astellas, and the Prostate Cancer Foundation. DJG reports personal fees from Advanced Accelerator Applications, American Association for Cancer Research, AVEO Pharmaceuticals, Brown and James Atty, Eisai, IdeoOncology, Medscape Education, Merck Sharp & Dohme, Michael J Hennessey & Associates, Millennium Medical Publishing, Myovant Sciences, Nektar Therapeutics, Propella Therapeutics, Seattle Genetics, UroGPO, UroTo-day, WebMD, WilmerHale Atty, and Xcures; grants and personal fees from Astellas, AstraZeneca, Bayer H\/C Pharma, Exelixis, Janssen Pharma, Pfizer, and Sanofi; and grants from BMS, Novartis, and Calithera outside the submitted work. DMN reports grants from the Prostate Cancer Foundation during the conduct of the study, as well as personal fees from Janssen Oncology outside the submitted work. RS reports consulting\/advisory board: J&J, Bayer, Merck, Amgen. DCD reports support from the US Department of Defense, American Society of Clinical Oncology, Prostate Cancer Foundation, Stand Up 2 Cancer, Amgen, Janssen Research & Development, Astellas, and Medivation. Consultant for Janssen Research & Development, AstraZeneca, BioView LTD, Clovis, Astellas, Medivation, Sanador, Angle LLT, Pfizer, Merck, and Amgen. RZS Consulting\/advisory board: J&J, Bayer, Merck, Amgen. JL has served as a paid consultant\/advisor for Sun Pharma, has received research funding to his institution from Sanofi, AstraZeneca, Calibr, and Cardiff Oncology, and is the lead inventor of AR-V7-related technologies owned by Johns Hopkins University and licensed to Qiagen and A&G. ESA reports grants and personal fees from Janssen, Johnson & Johnson, Sanofi, Bayer, Bristol Myers Squibb, Convergent Therapeutics, Curium, MacroGenics, Merck, Pfizer, and AstraZeneca; personal fees from Aadi Bioscience, Abeona Therapeutics, Aikido Pharma, Astellas, Amgen, Blue Earth, Boundless Bio, Corcept Therapeutics, Duality Bio, Exact Sciences, Hookipa Pharma, Invitae, Eli Lilly, Foundation Medicine, Menarini-Silicon Biosystems, Tango Therapeutics, Tempus, Tolmar Scientific, VIR Biotechnology, and Z-alpha; grants from Novartis, Celgene, and Orion; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen. FUNDING: ESA is partially supported by NCI grant P30 CA077598 and DOD grant W81XWH-22-2-0025. AJA reports research support (to Duke) from the NIH\/NCI, PCF\/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis. AJA reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, Telix.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}